The good, the bad, and the modified: CYLD’s post-translational tale
The deubiquitinating enzyme CYLD hydrolyzes Lys63-and Met1-linked ubiquitin chains, playing a crucial role in regulating various cellular processes such as immune cell development, innate and adaptive immunity, spermatogenesis, ciliogenesis, and cell survival. CYLD also functions as a tumor suppressor and is mutated in familial cylindromatosis. This pleiotropic function implies tight regulatory mechanisms. In this review, we summarize the current knowledge on CYLD’s molecular characteristics, subcellular location, and binding partners, with a focus on its involvement in life-and-death decisions. In addition, we discuss how post-translational modifications, including phosphorylation, ubiquitination, and proteolysis, shape CYLD’s function, unveiling the potential for therapeutic intervention. Finally, we highlight the remaining challenges that need to be overcome to deepen our understanding of this crucial enzyme.
Authors
- Nicolas Bidère (ORCID: https://orcid.org/0000-0001-9177-0008)
- Tiphaine Douanne (ORCID: https://orcid.org/0000-0001-8197-8358)
- Yanis M. Macé
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (FR)
- La Ligue Contre le Cancer (FR)
- Nantes Université (FR)
Publication Details
- Journal
- Frontiers in Cell Death
- Published
- 2025-04-09
- DOI
- https://doi.org/10.3389/fceld.2025.1583221
- Citations
- 3
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Institut National de la Santé et de la Recherche Médicale
- Fondation ARC pour la Recherche sur le Cancer
- Institut National Du Cancer
- Fondation Bettencourt Schueller
- Direction Générale de l’offre de Soins